NTLA Intellia Therapeutics, Inc.
Healthcare$12.45+0.00%OpenMarket Cap: $1.40B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.40
P/S
21.39
EV/EBITDA
-3.42
DCF Value
$-17.08
FCF Yield
-25.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-31.9%
Operating Margin
-636.6%
Net Margin
-597.0%
ROE
-57.3%
ROA
-52.0%
ROIC
-60.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $15.0M | 85.4% | $-100.5M | $-96.2M | $— | — |
| Q4 null | $23.0M | 73.9% | $-98.7M | $-95.8M | $— | — |
| FY null | $67.7M | 76.5% | $-441.0M | $-412.7M | $— | — |
| Q3 null | $13.8M | -472.8% | $-111.5M | $-101.3M | $— | — |
| Q2 null | $14.2M | 100.0% | $-110.0M | $-101.3M | $— | — |
| Q1 null | $16.6M | 100.0% | $-120.8M | $-114.3M | $— | — |
| Q4 null | $12.9M | 100.0% | $-136.4M | $-128.9M | $— | — |
| FY null | $57.9M | 82.2% | $-534.3M | $-519.0M | $— | — |
| Q3 null | $9.1M | 100.0% | $-144.8M | $-135.7M | $— | — |
| Q2 null | $7.0M | 62.6% | $-139.0M | $-147.0M | $— | — |
| Q1 null | $28.9M | 91.3% | $-114.0M | $-107.4M | $— | — |
| Q4 2023 | $-1.9M | 228.6% | $-139.9M | $-132.2M | $-1.46 | — |